Cargando…

Flow cytometry‐based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis

Systemic amyloid light chain (AL) amyloidosis is a life‐threatening protein deposition disorder; however, effective therapy can dramatically improve the prognosis of AL patients. Therefore, accurate diagnosis of the underlying hematologic disease is important. Multi‐parameter flow cytometry (MFC) is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lisenko, Katharina, Schönland, Stefan O., Jauch, Anna, Andrulis, Mindaugas, Röcken, Christoph, Ho, Anthony D., Goldschmidt, Hartmut, Hegenbart, Ute, Hundemer, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944872/ https://www.ncbi.nlm.nih.gov/pubmed/27109862 http://dx.doi.org/10.1002/cam4.725

Ejemplares similares

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis
por: Granzow, Martin, et al.
Publicado: (2017)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
por: Hegenbart, Ute, et al.
Publicado: (2017)

Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement
por: Berghaus, Natalie, et al.
Publicado: (2022)

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2022)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
por: Liebers, Nora, et al.
Publicado: (2022)

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2019)

Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis
por: Diao, Xiangwen, et al.
Publicado: (2017)

Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy
por: Aurich, Matthias, et al.
Publicado: (2023)

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis
por: Ochs, Marco M., et al.
Publicado: (2017)

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report
por: Feurstein, Simone, et al.
Publicado: (2022)

Prognostic Significance of Circulating Plasma Cells by Multi-Parametric Flow Cytometry in Light Chain Amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2018)

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
por: Arenja, Nisha, et al.
Publicado: (2019)

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
por: Wong, Sandy W., et al.
Publicado: (2018)

MR-Neurography of the sural nerve in patients with hereditary amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril
por: Pradhan, Tejaswini, et al.
Publicado: (2020)

Cardiac magnetic resonance strain imaging in systemic light chain amyloidosis
por: Andre, Florian, et al.
Publicado: (2014)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
por: Cuenca, Isabel, et al.
Publicado: (2020)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Amyloid in biopsies of the gastrointestinal tract—a retrospective observational study on 542 patients
por: Freudenthaler, Sophie, et al.
Publicado: (2016)

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE
por: Jaccard, A., et al.
Publicado: (2022)

Should we measure clonal circulating plasma cells in light chain amyloidosis?
por: Sidana, Surbhi, et al.
Publicado: (2018)

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
por: Minnema, Monique C., et al.
Publicado: (2019)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability
por: Pradhan, Tejaswini, et al.
Publicado: (2021)

Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2021)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Evaluation of laboratory diagnostic tests for light-chain clonality and bone marrow findings in AL amyloidosis
por: Lee, Taegeun, et al.
Publicado: (2023)

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation
por: Mosebach, Jennifer, et al.
Publicado: (2018)

Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation
por: Kazman, Pamina, et al.
Publicado: (2020)

Deferred autologous stem cell transplantation in systemic AL amyloidosis
por: Manwani, Richa, et al.
Publicado: (2018)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
por: Hein, Selina, et al.
Publicado: (2021)

The Value of Flow Cytometry Clonality in Large Granular Lymphocyte Leukemia
por: Giudice, Valentina, et al.
Publicado: (2021)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
por: Dittrich, Tobias, et al.
Publicado: (2019)

Localized Lymph Node Light Chain Amyloidosis
por: Dhakal, Binod, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_schh70hog7s01ii6qe9h1ph4qv